<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/swiper.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<style type="text/css">
	.content { font-size:16px; line-height:22px; }
	.content > h2 { margin-bottom:70px; }
	.content h4 { color:#b2d234; font-family:interstatebold; }
	.swiper-container.swiper-scroll { width:944px; height:460px; }
	.swiper-slide li, h4 { margin-bottom:10px; }
	.footnote { position:absolute; bottom:50px; left:0; }
	
</style> 
</head>
<body>
	<section id="container" data-slide="warning">
    	<nav class="nav-top icon">
            <ul>
                <li data-href="home"></li>
                <li data-href="warning">Contraindications<br />and Warnings</li>
                <li data-href="pi">PI</li>
                <li data-href="bibliography"></li>
                <li data-href="resource"></li>
                <li data-href="menu"></li>
            </ul>
        </nav>
    	<article class="content">
        	<!--subslides-->
            <h2>CONTRAINDICATIONS AND PRECAUTIONS</h2>
            <div class="swiper-container swiper-scroll">
                <ul class="swiper-wrapper">
                	<!-- slide 24-->
                    <li class="swiper-slide" data-slide="24">
                 		<p>
                        Lynparza<sup>™</sup> (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with platinum‑sensitive
relapsed BRCA‑mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal
cancer who are in response (complete response or partial response) to platinum-based chemotherapy.</p>
<p><strong>Contraindications:</strong></p>
<p>Hypersensitivity to the active substance or to any of the excipients listed in the SPC.</p>
<p>Breast-feeding during treatment and 1 month after the last dose.</p>
<p><strong>Special warnings and precautions for use:</strong></p>
<h4>Haematological toxicity</h4>
<p>Haematological toxicity has been reported in patients treated with Lynparza. Patients should not start treatment with
Lynparza&nbsp;until they have recovered from haematological toxicity caused by previous anticancer therapy.</p>
<ul class="list">
	<li>Baseline testing, followed by monthly monitoring, of complete blood counts is recommended for the first 12 months of
treatment and periodically after this time to monitor for clinically significant changes in any parameter during treatment.</li>
<li>If a patient develops severe haematological toxicity or blood transfusion dependence, treatment with Lynparza should be
interrupted and appropriate haematological testing should be initiated. If the blood parameters remain clinically abnormal
after 4 weeks of Lynparza dose interruption, bone marrow analysis and/or blood cytogenetic analysis are recommended</li>
</ul>   
<h4>Myelodysplastic syndrome/Acute Myeloid Leukaemia</h4>
<p>Myelodysplastic syndrome/Acute Myeloid Leukaemia (MDS/AML) have been reported in a small number of patients who received Lynparza alone or in combination with other anti-cancer drugs; the majority of cases have been fatal. </p>
<ul class="list">
	<li>If MDS and/or AML are confirmed while on treatment with Lynparza, it is recommended that the patient be treated
appropriately. If additional anticancer therapy is recommended, Lynparza should be discontinued and not given in
combination with other anticancer therapy</li>
</ul>
<h4>Pneumonitis</h4>
<p>Pneumonitis has been reported in a small number of patients receiving Lynparza, and some reports have been fatal.</p>
<ul class="list">
<li>If patients present with new or worsening respiratory symptoms such as dyspnoea, cough and fever, or a radiological
abnormality occurs, Lynparza treatment should be interrupted and prompt investigation initiated. If pneumonitis is
confirmed, Lynparza treatment should be discontinued and the patient treated appropriately</li>
</ul>
<h4>Embryofoetal toxicity</h4>
<p>Based on its mechanism of action (PARP inhibition), Lynparza could cause foetal harm when administered to a pregnant
woman.</p>
<h4>Pregnancy/contraception</h4>
<p>Lynparza should not be used during pregnancy and in women of childbearing potential not using reliable contraception
during&nbsp;therapy and for 1 month after receiving the last dose of Lynparza (see section 4.6).</p>
<h4>Interactions</h4>
<p>Lynparza co-administration with strong CYP3A inducers or inhibitors should be avoided.</p>
            		</li>
                    
            	</ul><!-- end swiper-wrapper -->
                <!-- Scroll Bar -->
                <div class="swiper-scrollbar"></div>
        	</div>
            <span class="footnote slim">*for full dosing and safety Information, please click here to see the Summary of Product Characteristics.</span>
        	<span class="logo lynp"></span>
        </article>
    
    	<!-- popup -->
        <div class="overlay">
            <!-- reference -->
            <div class="ref hide">
                <div class="item"> <span class="close icon"></span>
                    <h1>References</h1>
                    <ol></ol>
                </div>
            </div><!-- end ref -->
           <!-- navigation -->
            <div class="item nav hide"><span class="close icon"></span>
                <ul class="section">
                    <li data-href="1"><span>Unmet need</span></li>
                    <li data-href="2"><span>Mechanism<br />of action</span>
                        <ul>
                            <li data-href="2"><span>PARPi</span></li>
                            <li data-href="3"><span>DNA repair</span></li>
                        </ul>
                    </li>
                    <li data-href="4"><span>Clinical Data</span>
                        <ul>
                            <li data-href="4"><span>Extended PFS</span></li>
                            <li data-href="5"><span>Study overview</span></li>
                            <li data-href="6"><span>BRCAm<br />sub-analysis</span></li>
                            <li data-href="7"><span>TFST<br />Exploratory Analysis</span></li>
                            <li data-href="8"><span>TSST<br />Exploratory Analysis</span></li>
                            <li data-href="9"><span>Overall Survival</span></li>
                            <li data-href="10"><span><em>Post-Hoc</em> interim exploratory analysis of os</span></li>
                            <li data-href="11"><span>Patient Characteristics</span></li>
                        </ul>
                    </li>
                    <li data-href="12"><span>BRCAm+</span>
                        <ul>
                            <li data-href="12"><span>BRCAm testing</span></li>
                            <li data-href="13"><span>About BRCAm</span></li>
                            <li data-href="14"><span>Testing<br />guidelines</span></li>
                            <li data-href="15"><span>BRCAm status</span></li>
                        </ul>
                    </li>
                    <li data-href="16"><span>Patient<br />Support</span>
                	<ul>
                		<li data-href="17"><span>LYNPARZA Patient&nbsp;Access Programme</span></li>
                		<li data-href="18"><span>Patient&nbsp;Support Programme</span></li>
                		<li data-href="19"><span>Patient<br />Support Kit</span></li>
                		<li data-href="20"><span>Capsule<br />companion</span></li>
                	</ul>
                </li>
        		<li data-href="21"><span>Dosing &amp;<br />administration</span>
                	<ul>
                		<li data-href="21"><span>Safety and<br />tolerability</span></li>
                		<li data-href="22"><span>Dosing</span></li>
                	</ul>
                </li>
        		<li data-href="23"><span>Summary</span></li>
                </ul>
                
            </div><!-- end nav -->
        </div>
        
    </section>
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/TweenMax.min.js"></script>
<script type="text/javascript" src="js/TimelineLite.min.js"></script>
<script type="text/javascript" src="js/swiper.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){
		var swiperScroll = new Swiper('.swiper-scroll', {
			scrollbar: '.swiper-scrollbar',
			direction: 'vertical',
			slidesPerView: 'auto',
			mousewheelControl: true,
			freeMode: true,
			scrollbarDraggable: true,
			scrollbarHide: false
		});
		
		//swipe navigation
		goToNextOrPrevious(sections[10], sections[12]);
	})
</script>
</body>
</html>
